The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.

Lars Nilsson, Patrik Edén, Eleonor Olsson, Robert Månsson, Ingbritt Astrand-Grundström, Bodil Strömbeck, Kim Theilgaard-Mönch, Kristina Anderson, Robert Hast, Eva Hellström-Lindberg, Jan Samuelsson, Gösta Bergh, Claus Nerlov, Bertil Johansson, Mikael Sigvardsson, Ake Borg, Sten Eirik W Jacobsen

87 Citations (Scopus)

Abstract

Global gene expression profiling of highly purified 5q-deleted CD34+CD38(-)Thy1+ cells in 5q- myelodysplastic syndromes (MDSs) supported that they might originate from and outcompete normal CD34+CD38(-)Thy1+ hematopoietic stem cells. Few but distinct differences in gene expression distinguished MDS and normal stem cells. Expression of BMI1, encoding a critical regulator of self-renewal, was up-regulated in 5q- stem cells. Whereas multiple previous MDS genetic screens failed to identify altered expression of the gene encoding the myeloid transcription factor CEBPA, stage-specific and extensive down-regulation of CEBPA was specifically observed in MDS progenitors. These studies establish the importance of molecular characterization of distinct stages of cancer stem and progenitor cells to enhance the resolution of stage-specific dysregulated gene expression.
Original languageEnglish
JournalBlood
Volume110
Issue number8
Pages (from-to)3005-14
Number of pages9
ISSN0006-4971
DOIs
Publication statusPublished - 2007
Externally publishedYes

Fingerprint

Dive into the research topics of 'The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.'. Together they form a unique fingerprint.

Cite this